Galectin Therap

GALT

Current ValuationThe current P/E ratio is -12.05, below the reasonable range, cheaper than 95.86% of the time in the past 5 years, and the industry ranks 473/606, the industry Median -1.95.

-12.05xP/E
Stock price$3.35Earnings per share$-0.28

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
013263952

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-53.77x161.61%$207.66B
MRNAUSModerna
-28.94x16.99%$91.20B
CSLLYUSCSL Limited
-25.73x--$66.36B
NTRAUSNatera
-291.24x5.57%$56.02B
RVMDUSRevolution Medicines
-23.54x61.94%$41.63B
ROIVUSRoivant Sciences
-97.77x146.69%$26.03B
INSMUSInsmed
-37.66x75.15%$22.81B
BNTXUSBioNTech SE
-11.17x22.98%$21.83B
BBIOUSBridgebio Pharma
-24.44x31.08%$14.47B
SMMTUSSummit Therapeutics
-14.72x20.06%$12.60B
KYMRUSKymera Therapeutics
-30.24x8.45%$10.57B
MDGLUSMadrigal Pharma
-28.17x50.98%$9.16B
PCVXUSVaxcyte
-8.99x47.91%$9.57B
CYTKUSCytokinetics
-9.69x7.04%$8.66B
TWSTUSTwist Bioscience
-67.56x28.63%$9.24B
IBRXUSImmunityBio
-8.85x151.32%$8.79B
SYREUSSpyre Therapeutics
-58.27x45.60%$8.75B
ARWRUSArrowHead Pharma
-26.28x35,923.70%$8.41B
PRAXUSPraxis Precision Medicines
-23.09x3.71%$7.83B
IONSUSIonis Pharma
-11.89x49.51%$6.72B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.